Suppr超能文献

慢性移植物抗宿主病风险评分:国际血液和骨髓移植研究中心的分析。

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

机构信息

Department of Hematology, Oncology and Transplant, University of Minnesota, 420 Delaware St SE, Minneapolis MN 55455, USA.

出版信息

Blood. 2011 Jun 16;117(24):6714-20. doi: 10.1182/blood-2010-12-323824. Epub 2011 Apr 14.

Abstract

Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.

摘要

几种风险因素与慢性移植物抗宿主病(cGVHD)患者的死亡率增加相关,但报告的因素存在相当大的差异。因此,我们评估了 5343 例 cGVHD 患者的患者、移植和 cGVHD 特征,以制定风险评分。在总生存和非复发死亡率(NRM)的多变量分析中,确定了 10 个变量是显著的:年龄、既往急性移植物抗宿主病、从移植到 cGVHD 的时间、供体类型、移植时的疾病状态、GVHD 预防、性别不匹配、血清胆红素、卡氏评分和血小板计数。这 10 个变量用于构建 cGVHD 风险评分,并确定了 6 个风险组(RG)。RG1 的 5 年 NRM 为 5%(1%-9%),RG2 为 20%(19%-23%),RG3 为 33%(29%-37%),RG4 为 43%(40%-46%),RG5 为 63%(53%-74%),RG6 为 72%(59%-85%)。RG1 的 5 年总生存率最高,为 91%(95%置信区间[CI]:85%-97%),其次是 RG2 的 67%(65%-69%),RG3 的 51%(46%-55%),RG4 的 40%(37%-43%),RG5 的 21%(12%-30%),RG6 的 4%(0%-9%)(均<.01)。这项分析表明,从大型注册中心获取的数据对于制定主要移植结局的风险评分类别是有用的。需要在不同人群中验证这种 cGVHD 风险评分,以确保其广泛适用性。

相似文献

1
Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.
Blood. 2011 Jun 16;117(24):6714-20. doi: 10.1182/blood-2010-12-323824. Epub 2011 Apr 14.
7
Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study.
Biol Blood Marrow Transplant. 2016 Oct;22(10):1781-1791. doi: 10.1016/j.bbmt.2016.06.020. Epub 2016 Jun 22.
9
Evaluation of prognostic factors among patients with chronic graft-versus-host disease.
Haematologica. 2012 Aug;97(8):1187-95. doi: 10.3324/haematol.2011.055244. Epub 2012 Feb 27.

引用本文的文献

6
[Chinese expert consensus on the diagnosis and treatment of chronic graft-versus-host disease (2024)].
Zhonghua Xue Ye Xue Za Zhi. 2024 Aug 14;45(8):713-726. doi: 10.3760/cma.j.cn121090-20240611-00217.
9
Associations between acute and chronic graft-versus-host disease.
Blood Adv. 2024 Aug 27;8(16):4250-4261. doi: 10.1182/bloodadvances.2024013442.
10
Comparison of treatment response measures in cutaneous sclerosis after allogeneic hematopoietic cell transplantation.
Blood Adv. 2024 Sep 10;8(17):4651-4657. doi: 10.1182/bloodadvances.2024013233.

本文引用的文献

1
Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease.
Biol Blood Marrow Transplant. 2011 Jan;17(1):124-32. doi: 10.1016/j.bbmt.2010.06.018. Epub 2010 Jun 30.
2
Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.
Blood. 2009 Jul 16;114(3):702-8. doi: 10.1182/blood-2009-03-208983. Epub 2009 May 21.
4
Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival.
Biol Blood Marrow Transplant. 2007 Dec;13(12):1461-8. doi: 10.1016/j.bbmt.2007.08.006. Epub 2007 Oct 10.
8
Duration of immunosuppressive treatment for chronic graft-versus-host disease.
Blood. 2004 Dec 1;104(12):3501-6. doi: 10.1182/blood-2004-01-0200. Epub 2004 Aug 3.
9
Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study.
Blood. 2003 Aug 1;102(3):802-9. doi: 10.1182/blood-2002-10-3141. Epub 2003 Apr 24.
10
Chronic graft-versus-host disease: a prospective cohort study.
Biol Blood Marrow Transplant. 2003 Jan;9(1):38-45. doi: 10.1053/bbmt.2003.50003.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验